Zydus Lifesciences Limited has informed the Exchange regarding a press release dated August 31, 2023, titled "Zydus receives final approval from the USFDA for Isotretinoin Capsules USP, 10 mg, 20 mg 30 mg and 40 mg".
Press Release Aug 31 2023
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a press release announcing that it received final approval from the USFDA for Isotretinoin Capsules in various strengths. The capsules are intended for the treatment of severe cystic acne that has not responded to other treatments. The drug will be manufactured at Zydus' facility in Moraiya, Ahmedabad.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Aug 25 2023
- Press Release (Revised) Aug 24 2023
- Press Release Aug 24 2023
- Press Release Aug 17 2023
- Press Release Aug 11 2023
Later from Zydus Lifesciences
- Press Release Sep 01 2023
- Press Release Sep 13 2023
- Press Release Sep 15 2023
- Press Release Sep 19 2023
- Press Release Sep 20 2023
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences